Open AccessRestoring carbapenem efficacy: a novel carbapenem companion targeting metallo-β-lactamases in carbapenem-resistant Enterobacterales
Author(s) -
Nicola Ooi,
Victoria E. Lee,
Nathan Chalam-Judge,
Rebecca Newman,
Andrew J Wilkinson,
Ian Cooper,
David C. Orr,
Sally Lee,
Victoria J. Savage
Publication year - 2020
Publication title -
the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkaa455
Subject(s) - meropenem , carbapenem , microbiology and biotechnology , antimicrobial , escherichia coli , in vivo , biology , antibiotics , antibiotic resistance , gene , biochemistry
The dissemination of MBLs compromises effective use of many β-lactams in the treatment of patients with life-threatening bacterial infections. Predicted global increases in the prevalence of MBL-producing carbapenem-resistant Enterobacterales (CRE) are being realized, yielding infections that are untreatable with existing therapies including newly approved β-lactam/β-lactamase inhibitor combinations. Developing MBL inhibitors (MBLIs) now is essential to address the growing threat that MBL-producing CRE pose to patients.